Evidence Hub

Acetazolamide-Assisted Weaning From Mechanical Ventilation in a Child With Mixed Sleep Apnea: A Case Report

S. Tripathy, Sarbari Sarkar, Medhagopal R. G., Pradosh Kumar Sarangi, Archana Malik, Sarthak Das

Cureus, 2025

Abstract

An elevated central apnea-hypopnea index is typically considered indicative of abnormal breathing in children. Treatment of central sleep apnea (CSA) is complex, and multiple treatment options are tried with variable outcomes. Acetazolamide, a carbonic anhydrase inhibitor, is known to induce metabolic acidosis and can stimulate the respiratory drive. We report a 13-year-old boy who was having obesity and mixed apnea with an apnea-hypopnea index of 67.4/hour, who was hospitalized with hypercapnic respiratory failure. He was successfully weaned from prolonged mechanical ventilation following acetazolamide therapy. Post-discharge, he has had no apnea and continues to do well, with an improved quality of life at two months of follow-up. Acetazolamide use for central apnea/mixed apnea in children is very rare and not well established. Our case highlights the potential use of acetazolamide as an adjunct therapy in children with CSA, which needs further exploration.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free